Corvus Pharma Analyst Ratings
Corvus Pharma Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/07/2023 | 150% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
06/16/2023 | 118.75% | Mizuho | → $3.5 | Reiterates | Neutral → Neutral |
05/30/2023 | 525% | Ladenburg Thalmann | $4 → $10 | Maintains | Buy |
05/09/2023 | 150% | Cantor Fitzgerald | $2 → $4 | Maintains | Overweight |
03/30/2023 | 118.75% | Mizuho | → $3.5 | Reiterates | → Neutral |
10/07/2022 | 25% | Ladenburg Thalmann | → $2 | Initiates Coverage On | → Buy |
12/03/2021 | 400% | Cantor Fitzgerald | $5 → $8 | Maintains | Overweight |
12/01/2021 | 400% | Jefferies | → $8 | Initiates Coverage On | → Buy |
08/03/2021 | 118.75% | Mizuho | $4 → $3.5 | Maintains | Neutral |
07/16/2021 | 275% | HC Wainwright & Co. | $9.5 → $6 | Maintains | Buy |
05/27/2021 | 525% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
03/26/2021 | 493.75% | HC Wainwright & Co. | $12 → $9.5 | Maintains | Buy |
02/10/2021 | 150% | Mizuho | $7 → $4 | Downgrades | Buy → Neutral |
10/06/2020 | 650% | HC Wainwright & Co. | $10 → $12 | Maintains | Buy |
03/13/2020 | 400% | Wedbush | $11 → $8 | Maintains | Outperform |
03/10/2020 | 525% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
09/12/2019 | 337.5% | Mizuho | → $7 | Initiates Coverage On | → Buy |
05/29/2019 | 275% | Roth Capital | → $6 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
09/07/2023 | 150% | 坎托·菲茨杰拉德 | → 4 美元 | 重申 | 超重 → 超重 |
06/16/2023 | 118.75% | 瑞穗 | → 3.5 美元 | 重申 | 中性 → 中性 |
05/30/2023 | 525% | 拉登堡塔尔曼 | 4 美元 → 10 美元 | 维护 | 购买 |
05/09/2023 | 150% | 坎托·菲茨杰拉德 | 2 美元 → 4 美元 | 维护 | 超重 |
03/30/2023 | 118.75% | 瑞穗 | → 3.5 美元 | 重申 | → 中立 |
2022 年 7 月 10 日 | 25% | 拉登堡塔尔曼 | → 2 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 3 月 12 日 | 400% | 坎托·菲茨杰拉德 | 5 美元 → 8 美元 | 维护 | 超重 |
12/01/2021 | 400% | 杰富瑞 | → 8 美元 | 启动覆盖范围开启 | → 购买 |
08/03/2021 | 118.75% | 瑞穗 | 4 美元 → 3.5 美元 | 维护 | 中立 |
07/16/2021 | 275% | HC Wainwright & Co. | 9.5 美元 → 6 美元 | 维护 | 购买 |
05/27/2021 | 525% | 坎托·菲茨杰拉德 | → 10 美元 | 启动覆盖范围开启 | → 超重 |
2021 年 3 月 26 日 | 493.75% | HC Wainwright & Co. | 12 美元 → 9.5 美元 | 维护 | 购买 |
2021 年 10 月 2 日 | 150% | 瑞穗 | 7 美元 → 4 美元 | 降级 | 买入 → 中性 |
2020 年 6 月 10 日 | 650% | HC Wainwright & Co. | 10 美元 → 12 美元 | 维护 | 购买 |
03/13/2020 | 400% | Wedbush | 11 美元 → 8 美元 | 维护 | 跑赢大盘 |
2020 年 10 月 3 日 | 525% | HC Wainwright & Co. | → 10 美元 | 启动覆盖范围开启 | → 购买 |
2019 年 12 月 9 日 | 337.5% | 瑞穗 | → 7 美元 | 启动覆盖范围开启 | → 购买 |
05/29/2019 | 275% | 罗斯资本 | → 6 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Corvus Pharma (CRVS)?
Corvus Pharma(CRVS)的目标价格是多少?
The latest price target for Corvus Pharma (NASDAQ: CRVS) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $4.00 expecting CRVS to rise to within 12 months (a possible 150.00% upside). 6 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年9月7日公布了Corvus Pharma(纳斯达克股票代码:CRVS)的最新目标股价。该分析公司将目标股价定为4.00美元,预计CRVS将在12个月内上涨至150.00%(可能上涨150.00%)。去年有6家分析公司公布了评级。
What is the most recent analyst rating for Corvus Pharma (CRVS)?
Corvus Pharma(CRVS)的最新分析师评级是多少?
The latest analyst rating for Corvus Pharma (NASDAQ: CRVS) was provided by Cantor Fitzgerald, and Corvus Pharma reiterated their overweight rating.
Corvus Pharma(纳斯达克股票代码:CRVS)的最新分析师评级由坎托·菲茨杰拉德提供,Corvus Pharma重申了其增持评级。
When is the next analyst rating going to be posted or updated for Corvus Pharma (CRVS)?
Corvus Pharma(CRVS)的下一份分析师评级何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corvus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corvus Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
分析师在进行了广泛的研究后得出了股票评级,包括阅读公开财务报表、与Corvus Pharma的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级,因此每家公司每年应获得4个评级。Corvus Pharma的最新评级是在2023年9月7日提交的,因此你应该预计下一个评级将在2024年9月7日左右公布。
Is the Analyst Rating Corvus Pharma (CRVS) correct?
分析师对Corvus Pharma(CRVS)的评级是否正确?
While ratings are subjective and will change, the latest Corvus Pharma (CRVS) rating was a reiterated with a price target of $0.00 to $4.00. The current price Corvus Pharma (CRVS) is trading at is $1.60, which is within the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但重申了最新的Corvus Pharma(CRVS)评级,目标股价为0.00美元至4.00美元。Corvus Pharma(CRVS)目前的交易价格为1.60美元,在分析师的预测区间内。
译文内容由第三方软件翻译。